Q3 2023 Results

Existing brands Company overview Innovation: Pipeline overview Financial review Financial performance Novartis submission schedule Supplementary indications for existing brands Conclusions Appendix Innovation: Clinical trials References Abbreviations INNOVATION Cardiovascular Immunology Neuroscience Oncology Non-core TA project Kisqali® 2023 ribociclib, LEE011 HR+/HER2- BC (adj) XolairⓇ omalizumab, IGE025 Food allergy JakaviⓇ 2024 ruxolitinib, INC424 Pediatrics Acute GVHD JakaviⓇ ruxolitinib, INC424 Pediatrics Chronic GVHD LutatheraⓇ 177Lu-oxodotreotide¹ GEP-NET 1L G3 ScemblixⓇ ABL001 CML 1L Adakveo SEG101 Sickle cell disease, pediatrics Coartem® artemether+lumefantrine, COA566 Malaria uncompl., formula for <5kg 2025 Cosentyx® secukinumab, AIN457 GCA Leqvio® KJX839 Ped Hyperlipidemia ZolgensmaⓇ AVXS-101 OAV101 SMA IT BeovuⓇ brolucizumab, RTH258 Diabetic retinopathy PromactaⓇ eltrombopag, ETB115 Radiation sickness syndrome AimovigⓇ erenumab, AMG334 Pediatric Migraine Cosentyx® secukinumab, AIN457 Tendinopathy CosentyxⓇ secukinumab, AIN457 Polymyalgia rheumatica AtecturaⓇ indacaterol + mometasone, QMF149 Asthma, pediatrics KesimptaⓇ 2 ofatumumab Multiple sclerosis, pediatrics LeqvioⓇ KJX839 CVRR-LDLC 1. 177 Lu-dotatate in US. 2. Kesimpta and Mayzent: Pediatric trial in multiple sclerosis run in conjunction (NEOS). 39 Investor Relations | Q3 2023 Results ≥2026 LeqvioⓇ KJX839 Primary prevention MayzentⓇ 2 siponimod, BAF312 Multiple sclerosis, pediatrics RydaptⓇ midostaurin, PKC412 Acute myeloid leukemia, pediatrics ScemblixⓇ ABL001 CML, 2L, pediatrics NOVARTIS | Reimagining Medicine O

View entire presentation